If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Company Update

5 Jul 2013 07:00

RNS Number : 6665I
Ark Therapeutics Group PLC
05 July 2013
Β 

ο»Ώ

Ark Therapeutics Group plc

Β 

Company Update

Β 

London, UK, 5 July 2013 - Ark Therapeutics Group plc (LSE: AKT) ("Ark") has been notified by CrawfordΒ Healthcare Ltd ("Crawford") that it is of the view that certain sales of its productsΒ (KerraMax Care) do not constitute relevant sales for the purposes of theΒ earn-out consideration due to ArkΒ (subject to certainΒ revenue targets) under theΒ sale agreement dated 7 February 2011 pursuant to which Ark's woundcare business was sold to Crawford Woundcare Limited. As such, in Crawford's view it is unlikely that theΒ revenue targets will be met in respect ofΒ calendar year 2013. Ark strongly disagrees with the position Crawford is attempting to assert and, having taken legal advice, is confident that the product sales in question should be included in the relevant revenue targets which may or may not triggerΒ earn-out consideration. Whilst any payment to Ark of deferred consideration remains subject toΒ the agreed revenue targets being met inΒ calendar year 2013, and as such no guarantee can be given as to the likelihood of those targets being met, Ark is confident that on the basis of advice its position is sound and it will take all steps available to it to protect itsΒ contractual rights.

Β 

Non-Executive Director, David Venables, comments:

Β 

"We were initially contacted by Crawford Healthcare to discuss their position in April and since then the Company hasΒ taken independent legal advice on the detail of the contract. Discussions continue, and we hope to resolve the matter amicably with Crawford Healthcare."

Β 

A further update will be provided in due course.

Β 

For further information please contact:

Β 

Ark Therapeutics Group plc

Tel: +44 (0)207 002 1005Β 

Β 

Iain G Ross, Non-Executive Chairman

Β 

David Venables, Non-Executive Director

Β 

Β 

Β 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCLLFETDDISIIV
Date   Source Headline
16th Sep 20167:00 amRNSUS EXPANSION UPDATE AND ISSUE OF LOAN NOTES
7th Sep 20164:35 pmRNSPrice Monitoring Extension
5th Sep 20164:53 pmRNSContract Extension
1st Sep 20168:33 amRNSConfirmation of Capital Reduction Exercise
24th Aug 20165:16 pmRNSCapital Reduction
24th Aug 20163:14 pmRNSHolding(s) in Company
22nd Aug 201612:49 pmRNSDirector's Dealings
17th Aug 201610:56 amRNSDirector's Dealings
17th Aug 201610:56 amRNSHolding(s) in Company
1st Aug 201610:36 amRNSCooperation Agreement Signed With Zoetis
20th Jul 20167:00 amRNSAppointment of Chief Financial Officer
1st Jul 20167:00 amRNSAppointment of Broker
28th Jun 20167:00 amRNSFurther Major Agreement Signed in the US
27th Jun 20162:35 pmRNSHolding(s) in Company
24th Jun 201610:46 amRNSHolding(s) in Company
21st Jun 20164:10 pmRNSDirector's Dealings
21st Jun 201610:47 amRNSBlock Listing Application and Directors' Dealings
14th Jun 20163:44 pmRNSHolding(s) in Company
14th Jun 20163:39 pmRNSDirector's Dealings
10th Jun 20169:17 amRNSHolding(s) in Company
9th Jun 20167:00 amRNSPREMIER PET CARE PLAN LAUNCHED IN FRANCE
8th Jun 201610:57 amRNSDirector's Dealings
8th Jun 201610:48 amRNSHolding(s) in Company
8th Jun 201610:41 amRNSDirector's Dealings
7th Jun 201610:30 amRNSDirector's Dealings
3rd Jun 201612:41 pmRNSDirector's Dealings
2nd Jun 20167:00 amRNSMajor Agreement Signed in the US
9th May 20164:40 pmRNSSecond Price Monitoring Extn
9th May 20164:35 pmRNSPrice Monitoring Extension
9th May 201610:00 amRNSHolding(s) in Company
9th May 20167:00 amRNSHalf-year Report
5th May 20167:00 amRNSCONTROLLED EXPANSION INTO THE US
26th Apr 20167:48 amRNSRevised Strategy For Pet Care Plan Nordic Region
26th Apr 20167:00 amRNSBoard Changes
6th Apr 20164:40 pmRNSSecond Price Monitoring Extn
6th Apr 20164:35 pmRNSPrice Monitoring Extension
24th Mar 20169:00 amRNSDirector's Dealings
23rd Mar 201611:58 amRNSResult of AGM
23rd Mar 201611:38 amRNSAGM Statement
21st Mar 201610:17 amRNSDirector's Dealings
9th Mar 201611:36 amRNSBlock Listing Application - Withdrawal
8th Mar 20169:00 amRNSBlock Listing Application
2nd Mar 20164:09 pmRNSDirector's Dealings
29th Jan 20167:00 amRNSFinal Results
21st Dec 20157:00 amRNSDISPOSAL OF VETERINARY BUSINESS
20th Oct 20153:55 pmRNSHolding(s) in Company
17th Jul 201510:00 amRNSChange of website address
26th Jun 20153:28 pmRNSResult of AGM
17th Jun 201512:39 pmRNSDirector's Dealings
2nd Jun 20155:10 pmRNSBlocklisting Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.